Drug Profile
Pembrolizumab biosimilar - NeuClone/Serum Institute of India
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator NeuClone; Serum Institute of India
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Sep 2020 Preclinical trials in Cancer in Australia (Parenteral) prior to September 2020
- 01 Sep 2020 Preclinical trials in Cancer in India (Parenteral) prior to September 2020
- 01 Jun 2014 NeuClone and Serum Institute of India agree to co-develop ten biosimilar monoclonal antibodies in World for cancer and autoimmune disorders